The epidemiology and costs of implantable cardioverter–defibrillator therapy in Australia

Jitendra Vohra and Haris M Haqqani
Med J Aust 2018; 209 (3): . || doi: 10.5694/mja18.00601
Published online: 6 August 2018

The benefit of few medical interventions are as dramatic as the lifesaving effect of an ICD

Over the past three decades, implantable cardioverter–defibrillator (ICD) therapy has become the standard of care for preventing sudden cardiac death in a range of patients who are at particular risk. These patients can be broadly categorised into two groups: patients who have already been resuscitated from a sudden cardiac death event caused by a malignant ventricular arrhythmia (secondary prevention patients); and those who are deemed to be at increased risk because of the nature and severity of their cardiac diagnosis but have not had a malignant ventricular arrhythmia (primary prevention patients). Although new variants of the basic ICD platform, such as subcutaneous ICDs, are becoming available, the fundamental components of an ICD system remain constant: a lead for assessing cardiac rhythm, particularly the onset of a rapid malignant ventricular arrhythmia, and a pulse generator for rapidly delivering a direct current shock to terminate arrhythmia. In the appropriate setting, these devices can be live-saving, and the effects of few interventions in modern medicine are as compelling as the termination of ventricular fibrillation by an appropriate ICD shock.

  • 1 The Royal Melbourne Hospital, Melbourne, VIC
  • 2 Prince Charles Hospital, Brisbane, QLD


Competing interests:

No relevant disclosures.

  • 1. Connolly SJ, Hallstrom AP, Cappato R, et al. Meta-analysis of the implantable cardioverter defibrillator secondary prevention trials. AVID, CASH and CIDS studies. Antiarrhythmics vs Implantable Defibrillator study. Cardiac Arrest Study Hamburg. Canadian Implantable Defibrillator Study. Eur Heart J 2000; 21: 2071-2078.
  • 2. Moss AJ, Zareba W, Hall WJ, et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med 2002; 346: 877-883.
  • 3. Bardy GH, Lee KL, Mark DB, et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 2005; 352: 225-237.
  • 4. Goldberger JJ, Cain ME, Hohnloser SH, et al. American Heart Association, American College Of Cardiology, Heart Rhythm Society; Scientific statement on the noninvasive risk stratification techniques for identifying patients at risk for sudden cardiac death. J Am Coll Cardiol 2008; 52: 1179-1199.
  • 5. Bailey JJ, Berson AS, Handelsman H, Hodges M. Utility of current risk stratification tests for predicting major arrhythmic events after myocardial infarction. J Am Coll Cardiol 2001; 38: 1902-1911.
  • 6. Boveda S, Narayanan K, Jacob S, et al. Temporal trends over a decade of defibrillator therapy for primary prevention in community practice. J Cardiovasc Electrophysiol 2017; 28: 666-673.
  • 7. The 11th world survey of cardiac pacing and implantable cardioverter defibrillators: calendar year 2009 — a World Society of Arrhythmia project. Pacing Clin Electropphysiol 2011; 8: 1013-1027.
  • 8. Blanch B, Lago LP, Sy R, et al. Implantable cardioverter–defibrillator therapy in Australia, 2002–2015. Med J Aust 2018; 209: 123-129.
  • 9. Kober L, Thune JJ, Nielsen JC, et al. Defibrillator implantation in patients with nonischemic systolic heart failure. N Engl J Med 2016; 375: 1221-1230.


remove_circle_outline Delete Author
add_circle_outline Add Author

Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Online responses are no longer available. Please refer to our instructions for authors page for more information.